Expected Moves

The Read: Amneal Pharmaceuticals’ stock initially fell about 5% after a GAAP earnings miss despite adjusted beats and growth guidance, then dropped about 12% on debt concerns, surged about 13% after FDA approval of complex generics and a bullish UBS rating, but slipped 0%.